The intestine: A highly dynamic microenvironment for IgA plasma cells

Front Immunol. 2023 Feb 16:14:1114348. doi: 10.3389/fimmu.2023.1114348. eCollection 2023.

Abstract

To achieve longevity, IgA plasma cells require a sophisticated anatomical microenvironment that provides cytokines, cell-cell contacts, and nutrients as well as metabolites. The intestinal epithelium harbors cells with distinct functions and represents an important defense line. Anti-microbial peptide-producing paneth cells, mucus-secreting goblet cells and antigen-transporting microfold (M) cells cooperate to build a protective barrier against pathogens. In addition, intestinal epithelial cells are instrumental in the transcytosis of IgA to the gut lumen, and support plasma cell survival by producing the cytokines APRIL and BAFF. Moreover, nutrients are sensed through specialized receptors such as the aryl hydrocarbon receptor (AhR) by both, intestinal epithelial cells and immune cells. However, the intestinal epithelium is highly dynamic with a high cellular turn-over rate and exposure to changing microbiota and nutritional factors. In this review, we discuss the spatial interplay of the intestinal epithelium with plasma cells and its potential contribution to IgA plasma cell generation, homing, and longevity. Moreover, we describe the impact of nutritional AhR ligands on intestinal epithelial cell-IgA plasma cell interaction. Finally, we introduce spatial transcriptomics as a new technology to address open questions in intestinal IgA plasma cell biology.

Keywords: Aryl hydrocarbon (Ah) receptor; IgA; IgA plasma cells; intestinal epithelial barrier; intestinal epithelial cell; plasma cell; survival niche.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines
  • Immunoglobulin A
  • Intestinal Mucosa
  • Intestines*
  • Plasma Cells*

Substances

  • Cytokines
  • Immunoglobulin A

Grants and funding

This work was in part funded by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) TRR130 project 09 (GEPRIS DFG project number: 215346292) to H-MJ and WS, the DFG GRK2599 to H-MJ and intramural funding by the Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Friedrich-Alexander-Universität Erlangen-Nürnberg to KP. We acknowledge financial support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg within the funding programme “Open Access Publication Funding".